Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica
Résumé
Introduction: Recent studies suggested that anti-CD20 and fingolimod may be associated with lower anti-spike protein-based immunoglobulin-G response following COVID-19 vaccination. We evaluated if COVID-19 occurred despite vaccination among patients with multiple sclerosis (MS) and neuromyelitis optica (NMO), using the COVISEP registry. Case series: We report 18 cases of COVID-19 after two doses of BNT162b2-vaccination, 13 of which treated with anti-CD20 and four with fingolimod. COVID-19 severity was mild. Discussion: These results reinforce the recommendation for a third COVID-19 vaccine dose among anti-CD20 treated patients, and stress the need for a prospective clinical and biological study on COVID-19 vaccine efficacy among MS and NMO patients.
Domaines
Maladies infectieuses
Fichier principal
Januel et al. - 2021 - Post-vaccine COVID-19 in patients with multiple sc.pdf (829.9 Ko)
Télécharger le fichier
| Origine | Fichiers produits par l'(les) auteur(s) |
|---|